Cingulate (CINGW) Non Operating Income (2021 - 2025)
Cingulate's (CINGW) quarterly Non Operating Income came in at -$573058.0 in Q3 2025, down 1235.15% on a YoY basis from $50483.0 in Q3 2024, and down 492.88% quarter-over-quarter from -$96656.0 in Q1 2025.
Powered by 
Analysis
Cingulate (CINGW) Non Operating Income (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Non Operating Income for 5 consecutive years, with -$573058.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Income fell 1235.15% year-over-year to -$573058.0; the trailing twelve-month figure through Sep 2025 stood at -$542721.0 (down 372.67% YoY), and the FY2024 full-year result was $99236.0, up 112.79% from the prior year.
- Non Operating Income slipped to -$573058.0 in Q3 2025 per CINGW's latest filing, from -$96656.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $76510.0 in Q4 2024 and bottomed at -$573058.0 in Q3 2025.
- Historically, Non Operating Income has averaged -$86195.2 across 5 years, with a median of -$17409.5 in 2021.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income soared 255.17% in 2022, then sank 3133.93% in 2023.
- Over 5 years, Non Operating Income stood at -$6599.0 in 2021, then plunged by 1870.03% to -$130002.0 in 2022, then decreased by 5.8% to -$137546.0 in 2023, then jumped by 155.63% to $76510.0 in 2024, then plunged by 849.0% to -$573058.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$573058.0, -$96656.0, and $76510.0 for Q3 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.70 Bn | 623.94 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.16 Bn | 434.59 Bn | 12.70 Bn | - |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.48 Bn | 258.79 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.53 Bn | 45.15 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.20 Bn | 44.20 Bn | - | -139.24 Mn |
| 8 | Incyte | 25.27 Bn | 20.74 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 41.90 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -573,058.00 |
| Mar 31, 2025 | -96,656.00 |
| Dec 31, 2024 | 76,510.00 |
| Sep 30, 2024 | 50,483.00 |
| Jun 30, 2024 | -3,497.00 |
| Mar 31, 2024 | -24,260.00 |
| Dec 31, 2023 | -137,546.00 |
| Sep 30, 2023 | -229,380.00 |
| Jun 30, 2023 | -253,940.00 |
| Mar 31, 2023 | -154,892.00 |
| Dec 31, 2022 | -130,002.00 |
| Sep 30, 2022 | -58,885.00 |
| Jun 30, 2022 | 8,370.00 |
| Mar 31, 2022 | 5,833.00 |
| Dec 31, 2021 | -6,599.00 |
| Sep 30, 2021 | -10,559.00 |
| Jun 30, 2021 | -9,676.00 |
| Mar 31, 2021 | -3,759.00 |